How Private Equity Funds Value Portfolio Companies

Private equity funds must value their portfolio companies quarterly for net asset value reporting, even when no sale occurs. They blend entry multiples, discounted cash flow analysis, and market comparables under IPEV (International Private Equity and Venture Capital Valuation) guidelines to produce defensible marks that can shift significantly between quarters.

The regulatory mandate: IPEV guidelines

Private equity funds are not publicly traded; their investors (limited partners) own shares through the fund’s accounting vehicle. To report quarterly performance and net asset value, the fund must estimate the value of each portfolio company in the absence of an active market price.

The IPEV Guidelines set the standard. Issued by the International Private Equity & Venture Capital Association, these principles require funds to:

1. Value at fair value (not cost, not forced liquidation price).
2. Use multiple techniques when no single method is conclusive.
3. Document assumptions and sensitivities.
4. Adjust valuations when material changes occur (acquisitions, profit warnings, credit downgrades of the company or its lenders).
5. Consider external benchmarks and recent transactions to reality-check internal estimates.

Adherence to IPEV is not legally mandatory everywhere, but it is the de facto standard. Many LP agreements and regulatory bodies reference it explicitly. Deviation invites LP scrutiny and auditor challenges.

Three core valuation methods

Private equity funds typically layer three approaches:

1. Entry Multiple Method

The simplest: apply the multiple paid at acquisition to the current EBITDA (or revenue). If you bought a company at 8× EBITDA for $100 million (implying $12.5 million EBITDA), and EBITDA has grown to $15 million, the entry multiple approach values it at 8× $15M = $120 million.

Pros:

• Objective and repeatable.
• Anchors to actual price paid.

Cons:

• Ignores multiple expansion or compression (the market may now demand 10× or 6× for similar companies).
• Stale if market conditions have shifted sharply.

Entry multiple is useful as a sanity check but rarely the sole basis for quarterly marks.

2. Discounted Cash Flow (DCF) Valuation

Project the company’s free cash flows 3–10 years forward, then discount them to present value using a discount rate that reflects the company’s risk (often 10–15% for private equity holdings). Add a terminal value (assuming perpetual growth or a modest exit multiple) to account for cash flows beyond the explicit forecast period.

Formula (simplified):

Value = (FCF Year 1 / (1 + discount rate)^1) + ... + (Terminal Value / (1 + discount rate)^n)

Pros:

• Forward-looking; reflects management’s own plan.
• Sensitive to operational improvements (the main driver of PE returns).

Cons:

• Highly assumption-dependent; small changes in growth rate or discount rate swing value by 20%+.
• Easy to bias (inexperienced valuers can justify any number).

A rigorous PE valuer stress-tests the DCF across scenarios (base case, upside, downside) and flags when DCF diverges sharply from market comparables.

3. Comparable Transactions and Precedent Sales

Identify recent M&A deals for similar companies in the same or adjacent industries. What multiples paid (EV/EBITDA, EV/revenue) in the last 12–24 months? Apply those multiples to the portfolio company’s current financials.

Example: If three “comp” deals for similar SaaS companies traded at 10–12× revenue in the past year, and your portfolio company has $50 million revenue, a reasonable range is $500M–$600M in value.

Pros:

• Market-grounded; hard to argue with recent actual prices.
• Reflects appetite and sentiment in the current environment.

Cons:

• Limited universe of comps; exact matches are rare.
• One large outlier deal can skew perception.
• Lag: deals take months to close, so comparable prices are stale by quarter-end.

How the three methods converge to a mark

A disciplined valuation process produces a range:

The fund’s valuation committee reviews these, weights them by confidence, and selects a point estimate—often the median or a weighted average. They document the judgment in writing for audit purposes.

If the three methods diverge wildly (e.g., DCF says $80M but comps say $150M), that signals either bad assumptions in one method or genuine ambiguity about the company’s prospects. The committee then investigates: Is the management team sandbagging in the DCF? Are the comps truly comparable? The mark is updated only after reconciling the gap.

Why marks change quarterly (even without a sale)

A portfolio company’s value can shift 10–20% quarter to quarter without any external event. The drivers:

1. Financial performance: If the company missed revenue targets, EBITDA multiples fall. Hit them, and the mark rises.
2. Multiple compression or expansion: If comparable companies in the sector just traded at lower multiples due to recession fears, the fund may mark down its holding even if the portfolio company itself performed fine.
3. Interest-rate moves: Higher discount rates reduce DCF value; lower rates increase it.
4. Management changes: A departing CFO or missed strategic milestone might lower conviction in the base-case plan.
5. Leverage or credit facility changes: If the portfolio company’s bank reduces its credit line or tightens covenants, debt becomes more expensive, reducing equity value.

These mark changes are real from an LP perspective—they reflect changed economics—but they are not yet “realized” gains or losses. Only when the company is sold or distributed does the mark become a final outcome.

Mark discipline and audit controls

Audit firms scrutinize PE valuations heavily. Many funds employ:

• Independent valuation specialists (not the deal team itself) to challenge in-house estimates.
• Valuation committees with representatives from operations, finance, and risk.
• Sensitivity analysis: “If EBITDA grows 2% instead of 3%, value drops to $X.”
• Quarterly reviews against actual reported results (comparing DCF assumptions to realized performance).

Auditors also ask: Has this company’s valuation moved more or less than comparables in its peer group? If your mark is an outlier, justify it or change it.

Fair value ≠ realizable value

A critical distinction: the quarterly mark is an estimate of fair value under IPEV guidelines. It is not:

• Cost basis (the price paid, used for tax and capital gains reporting).
• Liquidation value (what you could realize in a distressed sale).
• Asking price (what the fund would demand in a sale; typically higher than fair value).
• Guaranteed exit price (market conditions at exit time may differ sharply).

An LP might see a company marked at $150 million quarterly and assume that’s what the fund will exit for. In reality, the fund might sell for $160 million in a hot market or $130 million in a downturn. Fair value is the midpoint estimate under reasonable market conditions—not a forecast.

See also